2. Search Result
Search Result
Results for "

myelodysplastic syndrome

" in MedChemExpress (MCE) Product Catalog:

21

Inhibitors & Agonists

2

Peptides

5

Inhibitory Antibodies

3

Natural
Products

1

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-139076
    Menin-MLL inhibitor 19

    		Epigenetic Reader Domain Metabolic Disease Cancer
    Menin-MLL inhibitor 19, a potent exo-aza spiro inhibitor of menin-mll interaction, example A17, extracted from patent WO2019120209A1. Menin-MLL inhibitor 19 can be used for the reseaech of various diseases, such as cancer, myelodysplastic syndrome (MDS) and diabetes .
    Menin-MLL inhibitor 19
  • HY-15229
    Guadecitabine sodium
    Maximum Cited Publications
    10 Publications Verification

    SGI-110 sodium; S-110 sodium

    		 DNA Methyltransferase Cancer
    Guadecitabine sodium (SGI-110 sodium) is a second-generation DNA methyltransferases (DNMT) inhibitor for research of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) .
    Guadecitabine sodium
  • HY-16018A
    Ilorasertib hydrochloride

    ABT-348 hydrochloride

    		 Aurora Kinase PDGFR VEGFR Cancer
    Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib hydrochloride also is a potent VEGF, PDGF inhibitor. Ilorasertib hydrochloride has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) .
    Ilorasertib hydrochloride
  • HY-16018
    Ilorasertib

    ABT-348

    		 Aurora Kinase VEGFR PDGFR Cancer
    Ilorasertib (ABT-348) is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib also is a potent VEGF, PDGF inhibitor. Ilorasertib has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) .
    Ilorasertib
  • HY-159646
    BMS-986397

    		Molecular Glues Ligands for E3 Ligase Casein Kinase Apoptosis Cancer
    BMS-986397 is a cereblon-based CK1α (casein kinase 1α) molecular glue degrader that can cause rapid apoptosis and cell cycle arrest in TP53 wild-type AML (acute myeloid leukemia) cells. BMS-986397 can be used for the study of AML and HR-MDS (High-Risk Myelodysplastic Syndrome) .
    BMS-986397
  • HY-176197
    IRAK4-IN-31

    		IRAK Cancer
    IRAK4-IN-31 (Compound II) is a crystalline IRAK4 inhibitor. IRAK4-IN-31 can be used in myelodysplastic syndrome (MDS) research .
    IRAK4-IN-31
  • HY-132189
    Laniquidar

    		P-glycoprotein Cancer
    Laniquidar (R101933) is a noncompetitive, third generation P-glycoprotein (P-gp) inhibitor with an IC50 of 0.51 μM. Laniquidar can be used for modulating multidrug resistance transporters . Laniquidar can also be used for studying acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) . Laniquidar has limited oral bioavailability .
    Laniquidar
  • HY-P991425
    AT-1413

    		Transmembrane Glycoprotein Cancer
    AT-1413 is a human monoclonal antibody (mAb) targeting CD43. AT-1413 induces antibody-dependent cell-mediated cytotoxicity (ADCC) in melanoma cell lines and acute myeloid leukemia (AML) cells. AT-1413 has antitumor activity in AML mouse models. AT-1413 can be used in Acute myeloid leukaemia, Breast cancer, Malignant melanoma and Myelodysplastic syndromes research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    AT-1413
  • HY-13542
    Guadecitabine

    SGI-110

    		 DNA Methyltransferase Cancer
    Guadecitabine (SGI-110) is a second-generation DNA methyltransferases (DNMT) inhibitor for research of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) .
    Guadecitabine
  • HY-107724
    PD 160170

    		Neuropeptide Y Receptor Others
    PD 160170 is a compound developed to inhibit low-risk myelodysplastic syndrome-associated anemia with activities that promote red blood cell transfusion independence and increase hemoglobin.
    PD 160170
  • HY-13634
    Ezatiostat hydrochloride

    TER199; TLK199 hydrochloride

    		 Glutathione S-transferase Apoptosis Cancer
    Ezatiostat hydrochloride (TER199; TLK199 hydrochloride) is a tripeptide analog of glutathione and is a selective and orally active glutathione S-transferase P1-1 (GSTP1) inhibitor. Ezatiostat hydrochloride leads to JNK activation by inhibiting GSTP1. Ezatiostat hydrochloride stimulates both lymphocyte production and bone marrow progenitor proliferation. Ezatiostat hydrochloride has the potential for myelodysplastic syndrome (MDS) treatment .
    Ezatiostat hydrochloride
  • HY-113061
    Pseudouridine

    		Endogenous Metabolite Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Cancer
    Pseudouridine is an isomer of uridine and the most abundant modified nucleoside in non-coding RNA. It fine-tunes and stabilizes regional structures in rRNA and tRNA, maintaining their functions in mRNA decoding, ribosome assembly, processing, and translation. Pseudouridine-modified tRNA fragments can inhibit aberrant protein synthesis and hold promise for research on myelodysplastic syndrome (MDS)-related leukemia. .
    Pseudouridine
  • HY-13634A
    Ezatiostat
    5+ Cited Publications

    TER199(free base); TLK199

    		 Glutathione S-transferase Apoptosis Cancer
    Ezatiostat (TER199 free base; TLK199) is a tripeptide analog of glutathione and is a selective and orally active glutathione S-transferase P1-1 (GSTP1) inhibitor. Ezatiostat leads to JNK activation by inhibiting GSTP1. Ezatiostat stimulates both lymphocyte production and bone marrow progenitor proliferation. Ezatiostat has the potential for myelodysplastic syndrome (MDS) treatment .
    Ezatiostat
  • HY-P99445
    Asunercept

    APG101; CAN008

    		 TNF Receptor Inflammation/Immunology Cancer
    Asunercept (APG101; CAN008) is a soluble CD95-Fc fusion protein targeting CD95L. Asunercept disrupts CD95/CD95L signaling by selectively binding to CD95L. Asunercept can be used in the research of glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD) .
    Asunercept
  • HY-114226
    Olutasidenib
    1 Publications Verification

    FT-2102

    		 Isocitrate Dehydrogenase (IDH) Inflammation/Immunology Cancer
    Olutasidenib (FT-2102) is a highly potent, orally active, brain penetrant and selective inhibitor of mutant Isocitrate dehydrogenase 1 (IDH1), with IC50 values of 21.2 nM and 114 nM for IDH1- R132H and IDH1- R132C, respectively . Olutasidenib (FT-2102) is under the study in the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) .
    Olutasidenib
  • HY-P991560
    TQB-2928

    		CD47 Cancer
    TQB-2928 is a monoclonal antibody against CD47, which can be used in the study of cancer.
    TQB-2928
  • HY-W768571
    Pseudouridine-13C,15N2

    		Isotope-Labeled Compounds Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Endogenous Metabolite Cancer
    Pseudouridine- 13C, 15N2 is the 13C- and 15N-labeled Pseudouridine (HY-113061). Pseudouridine is an isomer of uridine and the most abundant modified nucleoside in non-coding RNA. It fine-tunes and stabilizes regional structures in rRNA and tRNA, maintaining their functions in mRNA decoding, ribosome assembly, processing, and translation. Pseudouridine-modified tRNA fragments can inhibit aberrant protein synthesis and hold promise for research on myelodysplastic syndrome (MDS)-related leukemia. .
    Pseudouridine-13C,15N2
  • HY-N2907
    Atranorin

    		Wnt Ras Endogenous Metabolite Bacterial Fungal PD-1/PD-L1 Tim3 Akt AP-1 STAT Infection Neurological Disease Inflammation/Immunology Cancer
    Atranorin is a secondary metabolite of lichens and AKT inhibitor. Atranorin possesses multiple activities such as antibacterial, anti-inflammatory, antioxidant, anti-glycation, analgesic, and anti-tumor effects. Atranorin has IC50 values for scavenging DPPH and ABTS free radicals of 117 μM and less than 10 μM, respectively. Additionally, Atranorin also exhibits effects in promoting wound healing. Atranorin can be used in the research of various diseases, including myelodysplastic syndromes, tumors, and inflammatory conditions .
    Atranorin
  • HY-P99521
    Vibecotamab

    XmAb14045

    		 CD3 Inflammation/Immunology Cancer
    Vibecotamab (XmAb14045) is a potent bispecific antibody targeting both CD123 and CD3. Vibecotamab targets T cell-mediated killing of CD123-expressing cells, regardless of T cell antigen specificity. Vibecotamab is a full length immunoglobulin molecule. Vibecotamab can be studied in research for diseases such as Myelodysplastic syndrome and acute myeloid leukemia. Recommend Isotype Control: half-IG G1-kappa/(scFv-heavy-lambda)-h-CH2-CH3 .
    Vibecotamab
  • HY-P99555
    Tomaralimab

    OPN-305

    		 Toll-like Receptor (TLR) MyD88 NOD-like Receptor (NLR) Tau Protein Interleukin Related Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Tomaralimab (OPN-305) is a humanized anti-TLR2 IgG4 monoclonal antibody. Tomaralimab inhibits TLR2, MyD88, NLRP3, and reduces pro-inflammatory cytokine (IL-1β, IL-6, IL-8) production. Tomaralimab reduces tau pathology. Tomaralimab improves cognition, atopic dermatitis. Tomaralimab has anticancer effects on pancreatic ductal adenocarcinoma. Tomaralimab is being studied in myelodysplastic syndrome (MDS), atopic dermatitis, pancreatic ductal adenocarcinoma, Alzheimer's disease, and myocardial ischemia/reperfusion injury .
    Tomaralimab
  • HY-N2907R
    Atranorin (Standard)

    		Wnt Reference Standards Ras Endogenous Metabolite Bacterial Fungal PD-1/PD-L1 Tim3 Akt AP-1 STAT Infection Neurological Disease Inflammation/Immunology Cancer
    Atranorin (Standard) is the analytical standard of Atranorin (HY-N2907). This product is intended for research and analytical applications. Atranorin is a secondary metabolite of lichens and AKT inhibitor. Atranorin possesses multiple activities such as antibacterial, anti-inflammatory, antioxidant, anti-glycation, analgesic, and anti-tumor effects. Atranorin has IC50 values for scavenging DPPH and ABTS free radicals of 117 μM and less than 10 μM, respectively. Additionally, Atranorin also exhibits effects in promoting wound healing. Atranorin can be used in the research of various diseases, including myelodysplastic syndromes, tumors, and inflammatory conditions .
    Atranorin (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: